Mode
Text Size
Log in / Sign up
Phase 3 Completed N=60 Randomized Quadruple-blind Treatment

Interleukin-1 Blockade in Recently Decompensated Heart Failure

Source: ClinicalTrials.gov NCT01936909 ↗
Enrolled (actual)
60
Serious AEs
32.7%
Results posted
Dec 2017
Primary outcomePrimary: Interval Changes in Peak Oxygen Consumption (VO2) — 14.05; 14.45; 13.3; 14.85 mL/kg/min — p=>0.20
◆ Published Evidence
Highly cited
235citations · ~26 / year
Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).
Circulation. Heart failure · 2017 · Open access · Likely link

Summary

The RED-HART is a randomized double-blinded placebo-controlled study of Anakinra (IL-1 blocker) in patients with recently decompensated heart failure to determine the safety and efficacy in terms of aerobic exercise capacity and ventilatory efficiency measured with a cardiopulmonary exercise test.

Linked Publications

  • Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).
    Circulation. Heart failure · 2017 · 235 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Interval Changes in Peak Oxygen Consumption (VO2)
14.05; 14.45; 13.3; 14.85; 14.45; 12.65 >0.20
SECONDARY
Quality of Life Improvement
26.95; 23.45; 22.825; 37.575; 34.45; 28.7 <0.01 sig
SECONDARY
Death or Hospital Admission for Heart Failure
4; 1; 3 0.12

Eligibility Criteria

Inclusion Criteria

All 6 criteria need to be met for enrollment of the patient in the study

  • Primary diagnosis for hospitalization is decompensated heart failure established as the finding at admission of all 2 conditions listed below:
  • dyspnea or respiratory distress or tachypnea at rest or with minimal exertion;
  • evidence of elevated cardiac filling pressure or pulmonary congestion (at least one of the conditions must be met);
  • pulmonary congestion/edema at physical exam OR chest X-Ray;
  • plasma Brain Natriuretic Peptide (BNP) levels ≥200 pg/ml;
  • invasive measurement of left ventricular end-diastolic pressure >18 mmHg or of pulmonary artery occluding pressure (wedge) >16 mmHg.
  • The patient has a prior documentation of impaired left ventricular systolic function (ejection fraction 2 mg/L.

Exclusion Criteria Subjects will not be eligible if they meet any of the following 15 exclusion criteria.

  • The primary diagnosis for admission is NOT decompensated heart failure, including diagnosis of acute coronary syndromes, hypertensive urgency/emergency, tachy- or brady-arrhythmias.
  • Concomitant clinically significant comorbidities that would interfere with the execution or interpretation of the study including but not limited to acute coronary syndromes, uncontrolled hypertension or orthostatic hypotension, tachy- or brady-arrhythmias, acute or chronic pulmonary disease or neuromuscular disorders affecting respiration.
  • Recent (previous 3 months) or planned cardiac resynchronization therapy (CRT), coronary artery revascularization procedures, or heart valve surgeries.
  • Previous or planned implantation of left ventricular assist devices or heart-transplant.
  • Chronic use of intravenous inotropes.
  • Recent (<14 days) use of immunosuppressive or anti-inflammatory drugs (not including Non-Steroidal Anti-Inflammatory Drugs [NSAIDs]).
  • Chronic inflammatory disorder (including but not limited to rheumatoid arthritis, systemic lupus erythematosus).
  • Active infection (of any type);
  • Chronic/recurrent infectious disease (including Hepatitis B virus [HBV], Hepatitis C virus [HCV], and HIV/AIDS).
  • Prior (within the past 10 years) or current malignancy.
  • Any comorbidity limiting survival or ability to complete the study.
  • End stage kidney disease requiring renal replacement therapy.
  • Neutropenia (<2,000/mm3) or Thrombocytopenia (<50,000/mm3).
  • Pregnancy.
  • Angina, arrhythmias, or electrocardiograph (ECG) changes that limit maximum exertion during cardiopulmonary exercise testing obtained during the baseline testing.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01936909) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search